Drug class
Praziquantel enantiomer; antischistosomal and cestocidal anthelmintic
Mechanism of action
Increases parasite membrane permeability to calcium ions, causing rapid muscle contraction, paralysis and tegumental damage, facilitating immune-mediated parasite clearance.
General use cases
- Treatment of schistosomiasis caused by susceptible Schistosoma species in children aged 3 months to 6 years under the paediatric arpraziquantel product authorisation; use is specific to the dispersible paediatric formulation
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
